AVIGEN(avgn) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVIGEN(avgn)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: CJ who wrote (157)	11/12/1999 2:47:00 PM
From: JMarcus	Read Replies (1) of 228

I took extensive notes at the SH meeting today. I'll publish them this evening. I've already taken too much time off work today. There wasn't much new news. They've agreed with the ASH to keep mum about the Phase I trial until they give their presentation at the ASH convention on December 3 or 4. They confirmed that a press release will be issued on the date they give the presentation. The Phase I trial includes 9 patients: 3 are administered a low dose of the vector, 3 a medium dose, and 3 a high dose. The subject matter of the ASH will be the low dose patients, one of which is now 5 months past the date of his dosing (it is a single intramuscular dose protocol--they inject the vector into the thigh; aside--the vector for Hemophilia A--Factor VIII will be injected into the liver). The CEO scoffed at my hypothetical about the attractiveness (to management) of being bought out by a big pharma company for $50 a share. They really want to keep control of their own destiny. They've got 2-1/2 years' worth of cash, which aint bad for a microcap biotech company these days. More this evening. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next